Enap (Enalapril)

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enap (Enalapril)

The medication Enap is a synthetic prescription drug used to manage cardiovascular conditions, known generically as Enalapril maleate. It is a cornerstone treatment that works by intervening in the body's natural processes that control blood pressure.

Property Description
Active ingredient Enalapril maleate
Form Oral tablet, Oral solution
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
General purpose Decreases resistance in the circulatory system
Origin Synthetic compound

What Type of Medicine is Enap (Enalapril)?

Enap is the brand name for the active substance Enalapril maleate, which is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor and is an essential cardiovascular agent. The role of ACE inhibitors in managing cardiovascular conditions is clinically recognized. This categorization means the drug influences the systems that regulate blood pressure and fluid balance. The product is consistently designated as a prescription-only medication (Rx), reflecting its systemic action and required medical oversight.


Composition and General Purpose

Enalapril is a single-ingredient product supplied primarily as an oral tablet for systemic administration. A key feature specific to the Enalapril entity is its status as a prodrug, which means the molecule is chemically structured to become active only after metabolism converts it into the effective metabolite, Enalaprilat. The general therapeutic purpose of Enalapril is to decrease resistance within the circulatory system, thereby lessening the chronic strain and workload on the heart muscle. By facilitating vasodilation, the medication improves blood flow dynamics, making Enalapril a standard therapeutic choice for long-term cardiovascular support.

Regulatory References

  1. Enalapril: MedlinePlus Drug Information
  2. EPAR for Enalapril maleate

What side effects are possible with Enap (Enalapril)?

Possible Side Effects and Safety Information

The safety profile for Enalapril maleate (Enap) is defined by mandatory government regulatory documents (e.g., FDA Prescribing Information and EMA Summary of Product Characteristics). This information is grouped by frequency and the body system affected.

Frequency-Classified Adverse Reactions

Official labeling classifies adverse reactions based on their rate of occurrence in clinical trials:

Classification Examples of Reactions
Very Common (ge 10%) Dizziness, Cough, Asthenia, Blurred vision
Common (1% to <10%) Hypotension (low blood pressure), Headache, Fatigue, Nausea, Rash, Hyperkalaemia (high potassium)
Uncommon (0.1% to <1%) Renal failure, Pancreatitis, Tinnitus, Insomnia, Photosensitivity

Serious Adverse Reactions and Key Constraints

The regulatory safety profile highlights several serious adverse reactions and use limitations:

  • Angioedema: A critical safety risk involving swelling of the face, lips, tongue, or throat, which can be life-threatening due to potential airway obstruction.
  • Fetal Toxicity: Enalapril is contraindicated during pregnancy. Use during the second and third trimesters is documented to cause fetal injury and death.
  • Hypotension: Severe, symptomatic low blood pressure is a risk, particularly at treatment initiation or in patients with existing volume depletion.
  • Contraindications: Enalapril is prohibited for use in patients with a history of ACE inhibitor-related angioedema and must not be used concurrently with sacubitril/valsartan within a 36-hour period due to the risk of Angioedema. It is also contraindicated with aliskiren in patients who have diabetes or renal impairment.

Overdose and Emergency Response

An overdose of Enap (Enalapril), an Angiotensin-Converting Enzyme (ACE) inhibitor, requires immediate medical attention. The most common and significant symptom of an Enalapril overdose is severe hypotension (extremely low blood pressure). This can manifest as dizziness, fainting, profound weakness, and lightheadedness.


Recognizing Severe Symptoms

Other serious, though less frequent, symptoms of a massive overdose include:

  • Tachycardia (rapid heartbeat) or bradycardia (slow heartbeat).
  • Renal failure (decreased kidney function).
  • Circulatory shock, a life-threatening condition where the body cannot get enough blood flow.
  • Stupor or loss of consciousness.
Symptom Category Key Manifestations
Cardiovascular Severe Hypotension, Tachycardia, Bradycardia
Neurological Dizziness, Fainting, Stupor
Renal Acute Kidney Failure

Action Steps

If an overdose is suspected, or if the patient exhibits any of the severe symptoms listed above, immediately call emergency medical services (e.g., 911 in the U.S. or local equivalent) or a Poison Control Center. While awaiting help, the patient should be placed in the supine position (lying flat on their back) with their legs elevated to help maintain blood pressure. Do not induce vomiting unless specifically instructed to do so by medical professionals. Providing accurate information regarding the amount of Enalapril taken and the time of ingestion will assist emergency responders in treatment.

Therapeutic Uses of Enap (Enalapril)

What Enap (Enalapril) Treats: Main Uses and Benefits

Enalapril (Enap) is commonly used to help manage a range of cardiovascular conditions where functional stability becomes affected. The medicine plays a role in managing symptoms related to heightened physiological activity. It is applied across domains where additional symptomatic support is needed, relevant in conditions involving episodic or fluctuating manifestations.

Enalapril is considered relevant for easing symptoms related to physical discomfort and systemic imbalance across three core therapeutic domains: Hypertension (high blood pressure), Symptomatic Heart Failure, and Asymptomatic Left Ventricular Dysfunction.

In clinical scenarios where symptoms become temporarily overwhelming, Enalapril provides supportive relief. It assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.

The medicine contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Support for symptoms that create noticeable physiological strain.


Enalapril supports the patient during difficult episodes by easing distress and is commonly used in settings marked by temporary physiological imbalance.

Eligibility and Restrictions for Use

Official Eligibility Profile for Enap (Enalapril)

Enalapril eligibility is defined by regulatory documents, distinguishing between populations that are permitted, restricted, or strictly contraindicated.

Category Eligibility Rule
Absolute Contraindication Patients with a history of angioedema related to any ACE inhibitor, hereditary or idiopathic angioedema, or use during the second and third trimesters of pregnancy. Co-administration with aliskiren is prohibited in patients with diabetes or renal impairment.
Restricted Use/Caution Use requires special precautions in patients with impaired renal function (requiring careful monitoring), volume depletion, or hepatic impairment. Caution is also required in patients with aortic valve stenosis or hypertrophic cardiomyopathy.

Age and Reproductive Status: Use is established for adults and for children older than one month for hypertension. It is not recommended in infants one month of age or less, nor in pediatric patients with severe renal impairment (GFR < 30 mL/ min/1.73 m^2). The medicine must be discontinued immediately upon detection of pregnancy, and use is generally not recommended during breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Enap (Enalapril) is governed by formal regulatory restrictions and established pharmacokinetic patterns. This profile details combinations classified as contraindicated and specific substances that alter exposure or exhibit pharmacodynamic synergism.

Formal Restrictions and Contraindications

Enalapril is formally contraindicated for co-administration with medicinal products containing a Neprilysin Inhibitor (e.g., Sacubitril/Valsartan). A mandatory 36-hour separation window is required when switching between these two product classes. Co-administration with Aliskiren is also prohibited in patients with diabetes mellitus or those with documented renal impairment (eGFR below 60 mL/min/1.73 m^2).

Pharmacodynamic and Exposure Interactions

The use of Potassium-Sparing Diuretics (e.g., Amiloride, Spironolactone, Triamterene) and potassium supplements is documented to have an additive pharmacodynamic effect, increasing the risk of hyperkalemia (elevated serum potassium levels). Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause deterioration of renal function, a concern heightened in elderly or volume-depleted individuals. Regulatory labeling indicates that Enalapril can decrease the renal clearance of Lithium, leading to elevated serum concentrations of the co-administered agent. Food intake is officially documented as having no influence on the absorption of Enalapril maleate.

Mechanism of Action

Enalapril is a prodrug that undergoes hepatic hydrolysis by carboxylesterase 1 (CES1) to form its active metabolite, enalaprilat. Enalaprilat functions as a potent, competitive inhibitor of the angiotensin-converting enzyme (ACE), a zinc-metallopeptidase. ACE, which is identical to kininase II, catalyzes the conversion of angiotensin I to the potent vasoconstrictor, angiotensin II, within the renin-angiotensin-aldosterone system (RAAS), primarily in the vascular endothelium and kidneys.

Inhibition of ACE by enalaprilat reduces the systemic and local concentrations of angiotensin II. The decreased concentration of angiotensin II results in reduced stimulation of the AT1 receptors on vascular smooth muscle, causing a reduction in peripheral vascular resistance via vasodilation. Additionally, reduced angiotensin II leads to decreased stimulation of aldosterone secretion from the adrenal cortex, resulting in a reduction in renal tubular sodium and water reabsorption. Concurrently, ACE inhibition reduces the enzymatic degradation of the vasodilator peptide bradykinin. The molecular consequences of reduced vasoconstriction, reduced fluid volume, and potentiation of bradykinin result in a sustained modulation of systemic blood pressure and associated cardiovascular parameters.

Dosage and Administration Information

Instruction Map: How to use Enap (Enalapril) — Official Administration Guidelines


Administration Scope

Instruction Detail
Route of administration Primarily Oral (tablet and solution). The active metabolite, Enalaprilat, is administered Intravenously (IV).
Dosing schedule For adult hypertension, the initial dose is typically 5 mg once daily, or 2.5 mg daily if the patient is concomitantly taking a diuretic. The maximum dose is 40 mg daily. For heart failure, initiation is typically 2.5 mg once or twice daily, followed by titration.
Timing in relation to meals (if applicable) May be administered with or without food as the absorption process is not influenced by food intake.
Preparation requirements (if applicable) The oral solution formulation requires reconstitution with a specified diluent to achieve the label concentration of 1 mg/mL.
Age-group administration rules The starting dose for pediatric hypertension (over 1 month) is weight-based at 0.08 mg/kg once daily (max 5 mg). For adult patients with severe renal impairment (CrCL leq 30 mL/min), the initial dose is reduced to 2.5 mg once daily.
Missed-dose rules If a dose is missed, official instructions suggest taking it as soon as possible, or skipping the missed dose and resuming the normal schedule; a double dose should not be taken to compensate.
Special procedural conditions Therapy for heart failure must be initiated under close medical supervision. Dosage increases, or titration, are typically performed gradually over a period of two to four weeks.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral / Intravenous (via Enalaprilat)
Frequency pattern Once daily or twice daily (in divided doses).
Use-context constraints Requires initial dose reduction for patients with diuretic use or impaired renal function.

Resulting Procedural Structure

Official step sequence:

  • Initiation of long-term therapy must occur with a low, specified starting dose (2.5 mg or 5 mg).
  • Gradual titration of the dose must follow the initial period, increasing the amount over several weeks to reach the final maintenance dose.
  • The medicine must be taken once or twice daily, independently of meal timing.

Connection to the overall use protocol

The official instructions establish a long-term usage protocol characterized by a mandatory low-dose start and subsequent controlled, gradual dose escalation over time. This structured approach dictates the precise numerical ranges for initiation and maintenance, while also defining specific dose modifications required in the presence of reduced kidney function.

Recent Clinical Evidence

Research evidence / Overview of studies for Enap (Enalapril)


Evidence for use in High Blood Pressure (Hypertension)

Research has studied Enap (Enalapril) in numerous clinical trials to understand its role in managing high blood pressure, also known as hypertension. The research monitored outcomes related to systemic or functional imbalance, specifically research examined changes in blood pressure measurements. The data show patterns related to Enap and lower systolic blood pressure measurements when compared with an inactive substance in the studies. Some research describes patterns where Enap was observed in patients with changes in certain blood pressure measurements, compared to other medicines. Overall, the evidence contributes to understanding the patterns of blood pressure change observed in the study populations.


Evidence for use in Heart Failure

Enap (Enalapril) was evaluated in large-scale, long-term randomized controlled trials for individuals diagnosed with heart failure, specifically those with reduced heart pumping ability. This research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Long-term data show patterns related to Enap and patterns in major adverse clinical events (like death and hospitalization) in the populations studied. Other research describes patterns where use of Enap was observed in patients with changes in functional capacity and symptom scores. However, findings were mixed in studies of patients with a preserved heart pumping ability, suggesting that the patterns of response may differ depending on the specific type of heart failure.


Long-term studies and follow-up

Studies that explored the long-term effects of Enap in patients with heart failure have focused on follow-up periods that can span several years. These studies monitored long-term clinical events, such as hospitalizations, and attempted to quantify the durability of response across various phases of heightened symptom activity. For example, some analyses suggest that the main findings related to major adverse clinical events were most marked during the first couple of years of follow-up. It is important to note that there is limited information for long-term outcomes that go beyond the initial trial durations, and the full extent of the medicine’s long-term influence is not fully established.

Key Studies & References

  1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
  2. 2022 AHA/ACC/HFSA Heart Failure Guideline: Key Perspectives (Used for context on guideline placement and comparative use against newer drugs)

Frequently Asked Questions (FAQ)

Common questions about Enap (Enalapril) (FAQ)

Q: What is the main role of Enalapril in treating high blood pressure?

Official information states that Enalapril is used to treat high blood pressure (hypertension). It works by helping to modulate, or control, a system in the body called the renin-angiotensin-aldosterone system (RAAS). By influencing the RAAS, the medicine helps reduce peripheral vascular resistance, which contributes to lowering overall blood pressure.

Q: How quickly should someone expect to see a change in blood pressure after starting Enalapril?

According to the official product information and pharmacokinetic data, the onset of action for Enalapril when taken orally is generally seen within about one hour. Regulatory data indicates that the peak blood pressure-lowering effect is often observed within four to six hours after taking a dose.

Q: What is the cause of the persistent dry cough side effect associated with Enalapril?

Studies and official information indicate that this type of medicine affects the body’s metabolism of certain natural substances, including a peptide called bradykinin. Official explanations suggest that the accumulation of bradykinin is the mechanism putatively linked to the development of the dry cough.

Q: Is dizziness a common feeling when first starting Enalapril?

Yes, dizziness is listed as one of the commonly reported side effects in official documents for Enalapril. This is described as a possible effect related to the blood pressure modulation that occurs, especially when initiating treatment.

Q: What are the signs of angioedema, the serious swelling risk, while taking Enalapril?

Regulatory documents describe the signs of angioedema as sudden swelling of the face, lips, tongue, or throat, which may cause difficulty breathing or swallowing. This reaction is considered a serious safety concern and can occur at any time during treatment with this class of medication.

Q: Can Enalapril cause problems with kidney function?

Official warnings note that Enalapril can potentially cause a worsening of renal function (kidney function) in some patients. The use of this medicine has been associated with effects on kidney function, including reports of acute renal failure.

Q: What are the typical symptoms of high potassium (hyperkalemia) in people taking Enalapril?

Reported symptoms suggestive of high potassium levels include muscle weakness, a slow or irregular heartbeat, confusion, or a tingling sensation in the hands and feet. For this reason, monitoring potassium levels is typically part of the prescribed treatment protocol.

Q: Does Enalapril interact with non-prescription pain relievers like ibuprofen or naproxen?

Official drug interaction sections state that using Enalapril together with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen may pose two risks. It may reduce the drug's blood pressure-lowering effect and may increase the chance of worsening kidney function.

Q: Is it safe to use salt substitutes that contain potassium while taking Enalapril?

Regulatory guidance advises against the use of potassium-containing salt substitutes or potassium supplements when taking this medicine. This combination may lead to an excessive buildup of potassium in the blood, potentially reaching dangerous levels.

Q: How does drinking alcohol affect the action of Enalapril?

Official product information states that alcohol consumption may have additive effects with Enalapril in lowering blood pressure. This can result in an exaggerated drop in blood pressure, potentially leading to symptoms like dizziness or lightheadedness.

Q: Is there a known interaction between Enalapril and the medication Lithium?

Yes, regulatory documents warn that ACE inhibitors can reduce the clearance of Lithium from the body. This may lead to an increase in the amount of Lithium in the bloodstream, raising the potential for toxicity.

Q: Is it safe to continue taking Enalapril if I become pregnant?

Enalapril carries a Boxed Warning concerning fetal toxicity, which means it poses a risk of injury and death to a developing fetus. Official instructions state that the medicine should be discontinued as soon as possible if pregnancy is detected.

Q: Are there concerns about using Enalapril while breastfeeding?

Research from authoritative sources indicates that only low levels of the medication are typically found in breastmilk. Adverse effects in a breastfed infant would generally not be expected. Medical guidance is used to determine the appropriate course of action when breastfeeding.

Q: Is Enalapril appropriate for children and what age group is it typically used for?

Official regulatory approval specifies that Enalapril is indicated for the treatment of hypertension in children 6 years of age and older. The drug is prescribed for children under protocols that involve weight-based dosing and close medical monitoring.

Q: Are people with a history of angioedema still eligible to take Enalapril?

Official guidelines state that Enalapril is contraindicated and should not be used in individuals who have a history of angioedema related to prior treatment with any ACE inhibitor. It is also contraindicated for those with hereditary or idiopathic angioedema.

Q: Does a person's ethnicity (e.g., African-American descent) impact how Enalapril works?

Official clinical data notes that the blood pressure-lowering effects of ACE inhibitors, including Enalapril, may be less potent in Black patients compared to non-Black patients. Additionally, Black patients have been reported to have a higher incidence of angioedema.

Q: What kind of routine blood tests are required when taking Enalapril?

Monitoring protocols often recommend routine checks of renal function (how well the kidneys are working) and serum potassium levels. These checks are generally part of the prescribed monitoring during the initial phase of therapy and following dosage adjustments.

Q: Is it normal to feel a bit more tired or fatigued when starting Enalapril?

Fatigue is listed among the adverse reactions that have been reported in clinical trials and is considered a possible side effect of the medicine.

Q: What are the signs that Enalapril might be affecting the liver?

Although rare, signs of acute liver injury associated with this medication can include the development of jaundice (yellowing of the skin or eyes), significant fatigue, or unexplained itching. These symptoms require consultation with a healthcare professional.

Q: Is it necessary to stop taking Enalapril before having surgery or receiving general anesthesia?

Official clinical guidelines warn that patients taking Enalapril may be at risk for a marked drop in blood pressure (hypotension) during the induction of general anesthesia. For this reason, official protocols often advise withholding the medication before certain procedures.

Q: What is the meaning of the 'Black Box Warning' on Enalapril's official documentation?

The Black Box Warning is the FDA’s strongest cautionary notice, and for Enalapril, it highlights the serious and significant risk of fetal toxicity. It serves as a prominent warning about the potential for harm to an unborn baby.

Q: Does taking Enalapril affect how the body manages blood sodium levels?

The official warnings regarding the risk of excessive low blood pressure mention that patients with low blood sodium (hyponatremia) or those on a strict dietary salt restriction may be at increased risk. This suggests a careful balance of sodium is important while taking the drug.

Q: Why is it recommended to stand up slowly when taking Enalapril?

The recommendation to stand up slowly is to help mitigate the risk of symptomatic hypotension, or a drop in blood pressure upon standing. This effect is a known potential side effect related to the drug's overall blood pressure-lowering action.

Q: Can Enalapril cause changes to a person's sense of taste?

Official product information lists a change in or loss of taste sensation (dysgeusia) as one of the possible adverse effects that has been reported during the use of this medicine.

Q: Is it possible for Enalapril to cause stomach pain or digestive issues?

Adverse reactions reported in regulatory documentation include common gastrointestinal symptoms. These can manifest as nausea, vomiting, and diarrhea.

Q: What are the risks of taking Enalapril if someone is severely dehydrated?

Official warnings state that patients who are volume-depleted (e.g., due to severe dehydration, excessive sweating, or vomiting) are at increased risk for experiencing excessive hypotension when therapy with Enalapril is started.

Q: Can Enalapril be used in combination with diuretics (water pills)?

Yes, Enalapril is often used with diuretics, but official documents caution that this combination can increase the risk of excessive hypotension or acute renal failure. It may be necessary to adjust the dosage of the diuretic or Enalapril to manage this risk.

How should Enap (Enalapril) be stored and disposed of?

How to Store and Dispose of Enap (Enalapril)

This section outlines the official, regulatorily-mandated storage, handling, and disposal requirements for Enalapril, based on government-issued labeling.


Mandatory Storage and Handling

Condition Type Requirement Summary
Temperature Store tablets at room temperature, typically between 20 C and 25 C, and do not store above 30 C.
Environmental Protection Keep the container tightly closed and protect from moisture by storing in a dry place.
Freezing Do not freeze tablets or the reconstituted oral solution.
Child Safety Keep out of the reach of children.

Stability and Disposal Rules

Item Requirement Summary
In-Use Stability The reconstituted oral solution is stable for 60 days after preparation/dispensing; discard any unused portion after this time.
General Disposal Consult a healthcare professional or pharmacist on the correct method to dispose of unused or expired medication.
Environmental Rule Do not allow unused Enalapril or its waste to enter the sewer system, on the ground, or into any body of water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enap (Enalapril) found in:

A-Z Index: